Advertisement

Exkurs: Begleitende Behandlung von psychiatrischen Symptomen bei Morbus Parkinson

  • W. Danielczyk

Zusammenfassung

Verhaltensstörungen, Depressionen, isolierte kognitive Störungen, pharmakotoxische Psychosen und schließlich dementive Veränderungen werden in zunehmendem Maße bei Parkinson-Patienten beobachtet und mÜssen bei der Behandlung berÜcksichtigt werden. Zur Zeit James Parkinsons stand die Beurteilung der motorischen StÖrung vÖllig im Vordergrund. HÖhere psychische Funktionen — mit Ausnahme von Depressionen, seltenen sensorischen Mißempfindungen und im Finalstadium auftretende delirante Zustandsbilder — wurden im wesentlichen bis zur EinfÜhrung der modernen Anti-Parkinson-Therapie selten und nur am Rande beschrieben. In den letzten hundert Jahren hat sich die durchschnittliche Lebenserwartung in den Industriestaaten nahezu verdoppelt, und es kam zu einer explosionsartigen Zuwachsrate der Hochbetagten von mehreren 100 bis über 1000% (Rückert 1984).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Agid Y, Javoy-Agid F, Ruberg M (1987) Biochemistry of neurotransmitters in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworth, London, pp 166–230Google Scholar
  2. Ambrozi L, Danielczyk W (1988) Die Behandlung zerebraler FunktionsstÖrungen mit Memantine bei psychogeriatrischen Patienten — Ergebnisse einer Phase-II-Doppelblindstudie. Pharmacopsychiatry 21: 144–146PubMedCrossRefGoogle Scholar
  3. Andersen J, Aabro E, Gulmann N, Hjelmisted A, Pedersen HE (1980) Anti-depressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with PD treated with L-dopa. Acta Neurol Scand 62: 210–219PubMedCrossRefGoogle Scholar
  4. Baldessarini RJ, Marsh E (1990) Fluoxetine and side effects [Letter]. Arch Gen Psychiatry 47: 191–192PubMedCrossRefGoogle Scholar
  5. Baldessarini RJ, Frankenburg FR (1991) Clozapine: a novel antipsychotic agent. N Engl J Med 324: 740–754Google Scholar
  6. Baldwin RC, Benbow SM, Marriott A, Tomenson B (1993) Depression in old age. A reconsideration of cerebral disease in relation to outcome. Br J Psychiatry 163: 82–90PubMedCrossRefGoogle Scholar
  7. Barbeau A, Mars H, Gillo-Joffroy L (1971) Adverse clinical side effects of levo-dopa therapy. In: Mcdowell FH, Markham CH (eds) Recent advances in Parkinson’s disease. FA Davis, Philadelphia, pp 203–257Google Scholar
  8. Barber J, Tomer R, Sroka H, Myslobodsky MS (1985) Does unilateral dopamine deficit contribute to depression? Psychiatr Res 15: 17–24CrossRefGoogle Scholar
  9. Beasley BL, Nutt JG, Davenport R W, Chase TN (1980) Treatment with tryptophan of levodopa-associated psychiatric disturbances. Arch Neurol 37: 155–156PubMedCrossRefGoogle Scholar
  10. Ben-Shlomo Y, Marmot MG (1994) Survival and cause of death in Parkinson’s disease: possible clues to aetiology. Clin Neuropharmacol VIII/1: 143Google Scholar
  11. Birkmayer W, Riederer P (1980) Die Parkinson-Krankheit: Biochemie, Klinik, Therapie. Springer, Wien New York, S 167Google Scholar
  12. Bonner D, Howard R (1995) Treatment-resistant depression in the elederly. Int Psychogeriatr 7 [Suppl]: 83–94PubMedCrossRefGoogle Scholar
  13. Booth G (1948) Psychodynamics in parkinsonism. Psychosom Med 10: 1–4PubMedGoogle Scholar
  14. Bouchard RH, Pourcher E, Vincent P (1989) Fluoxetine and extrapyramidal side effects (Letters to the editor). Am J Psychiatry 146: 1352–1353Google Scholar
  15. Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH, Bohl J (1996) Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases. J Neural Transm 103: 455–490PubMedCrossRefGoogle Scholar
  16. Brannan T, Prikhojan A, Martínez-Tica J, Yahr MD (1995) In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. J Neural Transm 10: 79–89CrossRefGoogle Scholar
  17. Braun R, Jahanshahi M (1995) Depression in Parkinson’s disease: a psychosocial viewpoint. Adv Neurol 65: 61–84Google Scholar
  18. Brod TM (1989) Fluoxetine and extrapyramidal side effects (Letters to the editor). Am J Psychiatry 146: 1353Google Scholar
  19. Brown GI (1975) Parkinsonism depression and ECT. Am J Psychiatry 132: 1084Google Scholar
  20. Brown GL, Wilson WP (1972) Parkinsonism and depression. South Med J 65: 540–545PubMedCrossRefGoogle Scholar
  21. Brown RG, Maccarthy B, Gotham A-M, Der GJ, Marsden CD (1988) Depression and disability in Parkinson’s disease: a follow-up of 132 cases. Psychol Med 18: 49–55PubMedCrossRefGoogle Scholar
  22. Brücke T, Danielczyk W, Simayi M, Sofic E, Riederer P (1986) Terguride: partial dopamine agonist in the treatment of Parkinson’s disease. Adv Neurol 45: 573–576Google Scholar
  23. Burke WJ, Peterson J, Rubin EH (1988) Electroconvulsive therapy in the treatment of combined depression and Parkinson’s disease. Psychosomatics 29: 341–346PubMedCrossRefGoogle Scholar
  24. Caley CF, Friedmann JH (1992) Does fluoxetine exacerbate Parkinson’s disease? J Clin Psychiatry 53: 278–282PubMedGoogle Scholar
  25. Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF, Tomlinson BE (1983) Pathological changes in the nucleus of Meynert in Alzheimer’s disease and Parkinson’s disease. J Neurol Sci 54: 277–289CrossRefGoogle Scholar
  26. Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13: 272–276PubMedCrossRefGoogle Scholar
  27. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99: 47–53CrossRefGoogle Scholar
  28. Celesia GG, Barr AN (1970) Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 23: 193–200PubMedCrossRefGoogle Scholar
  29. Celesia CG, Wannamaker WM (1972) Psychiatric disturbances in Parkinson’s disease. Dis Nerv Syst 33: 577–583PubMedGoogle Scholar
  30. Cooper JA, Sagar H, Doherty SM, Jordan N, Tidswell P, Sullivan EV (1992) Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain 115: 1701–1725PubMedCrossRefGoogle Scholar
  31. Cotzias GC, Papavasiliou PS, Gellene R (1969) Moditication of parkinsonism. Chronic treatment with 1-dopa. N Engl J Med 280: 337PubMedCrossRefGoogle Scholar
  32. Crow TJ, Johnstone EC, Mcclelland HA (1976) The coincidence of schizophrenia and parkinsonism: some neurochemical implications. Psychol Med 6: 227PubMedCrossRefGoogle Scholar
  33. Crystal H, Dickson D, Lizardi J, Davies P, Wolfson L (1990) Antemortem diagnosis of diffuse Lewy body disease. Neurology 40: 1523–1528PubMedCrossRefGoogle Scholar
  34. Damasio AR, Labo-Antunes J, Macedo C (1971) Psychiatric aspects in parkinsonism treated with 1-dopa. J Neurol Neurosurg Psychiatry 34: 502–507PubMedCrossRefGoogle Scholar
  35. Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Med Welt 24 (NF): 1278–1282PubMedGoogle Scholar
  36. Danielczyk W (1978) Akute psychische Störungen während der L-Dopa-Therapie von Parkinsonkranken. In: Fischer PA (Hrsg) Langzeitbehandlung des Parkinson-Syndroms. Schattauer, Stuttgart New York, S 211–218Google Scholar
  37. Danielczyk W (1979) Akute pahrmakotoxische Psychosen bei chronischen zerebralen Erkrankungen. Wien Med Wochenschr 129[Suppl 55]: 3–15Google Scholar
  38. Danielczyk W (1981) Die Behandlung von phar-makotoxischen Psychosen bei Parkinson-Patienten mit Clopenthixol. Wien Klin Wochenschr 93: 500–501PubMedGoogle Scholar
  39. Danielczyk W (1983) Various mental behavioural disorders in Parkinson’s disease, primary degenerative senile dementia, and multi infarction dementia. J Neural Transm 56: 161–176PubMedCrossRefGoogle Scholar
  40. Danielczyk W (1986) Akinetische Krisen, akinetische Endzustände und Sterbealter bei hospitalisierten Parkinson-Patienten. In: Fischer PA (Hrsg) Spätsyndrome der Parkinson-Krankheit. Editiones Roche, Basel, S 89–98Google Scholar
  41. Danielczyk W, Fischer P (1989) Parkinson’s disease: development of dementia in aging. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 9–17CrossRefGoogle Scholar
  42. Danielczyk W, Fischer P (1990a) Psychiatric complications and shift of death age in Parkinson’s disease. Adv Neurol 53: 405–410PubMedGoogle Scholar
  43. Danielczyk W, Fischer P (1990b) Neuroleptische Therapie bei Morbus Parkinson. In: Müller-Oerlinghausen B, Möller H-J, Rüther E (Hrsg) Thioxanthene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New York Tokyo, S 137–142Google Scholar
  44. Danielczyk W, Fischer P, Laussegger C (1988) Antiparkinson-Therapie und Psychopharmaka. AuslÖsung von Psychosen durch Dosissteigerungen und medikamentÖse Wechselwirkungen. In: Fischer PA (Hrsg) Modifizierende Faktoren bei der Parkinson-Therapie. Editiones Roche, Basel, S 187–200Google Scholar
  45. Danielczyk W, Simanyi M, Fischer P, Streifler M, Jellinger K (1989) Der differentialdiagnostische Wert des EEG im Verlauf von SDAT, MID und schwerer Depression im Alter. Forum Medizin, Gerontopsychiatrie: 245–264Google Scholar
  46. Desmet Y, Ruberg M, Serdau M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 45: 1161–1164CrossRefGoogle Scholar
  47. Dingemanse J (1993) An update of recent moclobemide interaction data. Int Clin Psychopharmacol 7: 167–180PubMedCrossRefGoogle Scholar
  48. Doonief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R (1992) An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 49: 305–307CrossRefGoogle Scholar
  49. Douyon R, Serby M, Klutchko B, Rotrosen J (1989) ECT and Parkinson’s disease revisited: a „naturalistic“ study. Am J Psychiatry 146: 1451–1455PubMedGoogle Scholar
  50. Dovenmuehle R H, Verwoerdt A (1963) Physical illness and depressive symptomatology. II. Factors of length and severity of illness and frequency of hospitalization. J Am Geriatr Soc 18: 260Google Scholar
  51. Dray A (1981) Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. J Physiol Paris 77: 393–403PubMedGoogle Scholar
  52. Dubois B, Ruberg M, Javoy-Agid F, Ploska A, Agid Y (1983) A subcortical-cortical cholinergic system is affected in Parkinson’s disease. Brain Res 288: 213–218PubMedCrossRefGoogle Scholar
  53. Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y (1987) Cholinergic-dependent cognitive deficits in Parkinson’s disease. Ann Neurol 22: 26–30PubMedCrossRefGoogle Scholar
  54. Dubois B, Defontaines B, Deweer B, Malapani C, Pillon B (1995) Cognitive and behavioral changes in patients with focal lesions of the basal ganglia. Adv Neurol 65: 29–41PubMedGoogle Scholar
  55. Ebmeier K, Calder S, Crawford J, Stewart L, Besson J, Mutch W (1990) Clinical features predicting dementia in idiopathic Parkinson’s disease: a follow-up study. Neurology 40: 1222–1224PubMedCrossRefGoogle Scholar
  56. Factor SA, Singer C (1992) Neuroleptic malignant syndrome. In: Lang AE, Weiner WJ (eds) Drug-induced movement disorders. Futura, Mount Kisco, pp 199–230Google Scholar
  57. Factor SA, Brown D, Molho ES, Podskalny GD (1994) Clozapine: a two year open trial in Parkinson’s disease patients with psychosis. Neurology 44: 544–546PubMedCrossRefGoogle Scholar
  58. Factor SA, Molho ES, Podskalny GD, Brown D (1995) Parkinson’s disease: drug-induced psychiatric states. Adv Neurol 65: 115–138PubMedGoogle Scholar
  59. Fahn S, Snider S, Prasad ALN, Lane E, Makadon H (1975) Normalization of brain serotonin by L-tryptophan in levodopa treated rats. Neurology 25: 861–865PubMedCrossRefGoogle Scholar
  60. Fall P-A, Ekman R, Granérus A-K, Thorell L-H, Wålinder J (1995) ECT in Parkinson’s disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. J Neural Transm 10: 129–140CrossRefGoogle Scholar
  61. Fibiger HC (1984) The neurogiological substrates of depression in Parkinson’s disease: a hypothesis. Can J Neurol Sci 11: 105–107PubMedGoogle Scholar
  62. Fischer PA (1996) Lehrbuch der Gerontopsychiatrie — praktische Gerontopsychiatrie. Enke, StuttgartGoogle Scholar
  63. Fischer PA, Schneider E, Jacobi P (1982) Depressive Verstimmungen bei Parkinson-Kranken im Langzeitverlauf. In: Fischer PA (Hrsg) Psychopathologie des Parkinson-Syndroms. Editiones Roche, Basel, S 139–152Google Scholar
  64. Fischer P, Danielczyes W, Simanyi M, Streifler MB (1990) Dopaminergic psychosis in advanced Parkinson’s disease. Adv Neurol 53: 391–397PubMedGoogle Scholar
  65. Förstl H, Besthorn C, Sattel H, Zerfass R, Geiger-Kabisch C Schreiter-Gasser, Hentschel F (1996) Volumetrische Himveränderugen und quantitatives EKG bei normalem Altern und Alzheimer-Demenz. Der Nervenarzt 67: 53–61PubMedCrossRefGoogle Scholar
  66. Fras I, Litin EM (1968) Mental symptoms as an aid in the early diagnosis of carcinoma of the pancreas. Gastroenterology 55: 191–198PubMedGoogle Scholar
  67. Frazer A Mendels J (1977) Use of 1-dope in depression. Adv Biochem Psychopharmacol 16: 671–675PubMedGoogle Scholar
  68. Friedman JH (1991) The management of the levodopa psychoses. Clin Neuropharmacol 14: 283–295PubMedCrossRefGoogle Scholar
  69. Friedman J H, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 39: 1219–1221PubMedCrossRefGoogle Scholar
  70. Fünfgeld EW (1972) Zweijährige Erfahrungen mit der Amantadintherapie bei Parkinsonismus. Ther Woche 39: 3282–3299Google Scholar
  71. Fünfgeld EW (1995) Computerised brain electrical activity findings of Parkinson patients suffering from hyperkinetic side effects (hypersensitive dopamine syndrome) and a review of possible sources. J Neural Transm [Suppl 46]: 347–361Google Scholar
  72. Fünfgeld KW, Zwischenbrugger H (1994) Hinweise auf eine cerebro-toxische Wirkung von hohen Dopa-Dosen bei der Parkinson-Krankheit. In: Huffmann G, Braune HJ, Henn KH (Hrsg) Extrapyramidalmotorische Erkrankungen. Einhorn Presse Verlag, S 344–349Google Scholar
  73. Garcia C, Reding M, Blass J (1981) Overdiagnosis of dementia. J Am Geriatr Soc 29: 407–410PubMedGoogle Scholar
  74. Gerlach J, Ahlfors UG, Amthor KF, Dencker SJ, Gravem A (1986) Effect of different neuroleptics in tardive dyskinesia and parkinsonism. Psychopharmacology 90: 423–429Google Scholar
  75. Goldstein M, Lew JY, Hata F, Lieberman A (1978) Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontology 25[Suppl I]: 76–85CrossRefGoogle Scholar
  76. Goodwin FK (1971a) Behavioral effects of 1-dopa in man. Sem Psychiatry 3: 477–492Google Scholar
  77. Goodwin FK (1971b) Psychiatric side effects of levodopa in man. JAMA 218: 1915–1920PubMedCrossRefGoogle Scholar
  78. Gotham AM, Brown R G, Marsden CD (1988) Depression in Parkinson’s disease: a qualitative and quantitative analysis. J Neurol Neurosurg Psychiatry 49: 381–389CrossRefGoogle Scholar
  79. Götz ME, Fischer P, Gsell W, Riederer P, Streifler M, Simanyi M, Müller F, Danielczyk W (1995) Platelet monoamine oxidase B activity in dementia: a 4 year follow-up. J Neural Transm [Gen Sect] 102: XVIIGoogle Scholar
  80. Granérus AK, Axelsson O, Fall P A, Fredriksson M, Hansson G, Lindvale B, Olsson JE (1994) High age at onset indication of low risk for Parkinson’s disease? Clin Neuropharmacol VIII/1: 119–120Google Scholar
  81. Greene P, Cote L, Fahn S (1993) Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. Adv Neurol 60: 703–706PubMedGoogle Scholar
  82. Growdon JH, Corkin S, Rosen TJ (1990) Distinctive aspects of cognitive dysfunction in Parkinson’s disease. Adv Neurol 53: 365–376PubMedGoogle Scholar
  83. Heinrich K, Tegeler J (1983) Dyskognitive, apathische und extrapyramidale Syndrome bei Langzeit-Neurolepsie. In: Hippius H, Klein HE (Hrsg) Therapie mit Neuroleptika. Perimed, ErlangenGoogle Scholar
  84. Herrschaft H (1992) Piracetam. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psychopharmaka, Bd 5. Parkinsonmittel und Nootropika. Springer, Wien New York, S 189–200Google Scholar
  85. Hershey L, Feldman B, Kim K, Commichau C, Lichter D (1991) Tremor at onset. Arch Neurol 48: 1049–1051PubMedCrossRefGoogle Scholar
  86. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442PubMedCrossRefGoogle Scholar
  87. Hofman A, Shulte W, Tanja T, van Duijn CM, Haaxma R, Lameris AJ, Otten VM, Saan RJ (1989) History of dementia and Parkinson’s disease in 1 st-degree relatives of patients with Alzheimer disease. Neurology 39: 1589–1592PubMedCrossRefGoogle Scholar
  88. Hubble JP, Koller WC (1995) The Parkinsonian personality. Adv Neurol 65: 43–48PubMedGoogle Scholar
  89. Huber SJ, Freidenberg DL, Shuttleworth EC, Paulson GW, Clapp LE (1989) Neuropsychological similarities in lateralized parkinsonism. Cortex 25: 461–470PubMedGoogle Scholar
  90. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181–184PubMedCrossRefGoogle Scholar
  91. Iverson S (1984) Cortical monoamines and behavior. In: Descarries L, Reader LA, Jasper HH (eds) Monoamine innervation of the cerebral cortex. Alan Liss, New York, p 349Google Scholar
  92. Jackson JA, Free GBM, Pike HV (1923) The psychic manifestations in paralysis agitans. Arch Neurol Psychiatry 10: 680–684CrossRefGoogle Scholar
  93. Jellinger KA, Bancher CH (1995) Structural basis of mental impairment in Parkinson’s disease. Neuropsychiatrie 9/1: 9–13Google Scholar
  94. Jenkins RB, Groh RH (1970) Mental symptoms in parkinsonian patients with L-dopa. Lancet ii: 177–180CrossRefGoogle Scholar
  95. Joborn C, Hetta J, Palmer M, Akerström G, Ljunghall S (1986) Psychiatric symptomatology in patients with primary hyperparathyroidism. Up J Med Sci 91: 77–87CrossRefGoogle Scholar
  96. Jouvent R, Abensour P, Bonnet AM, Widlocher D, Agid Y, Lhermitte F (1983) Antiparkinsonian and anti-depressant effects of high doses of bromocriptine: an independent comparison. J Affect Disord 5: 141–145PubMedCrossRefGoogle Scholar
  97. Keyser DL, Rodnitzky RL (1991) Neuroleptic malignant syndrome in Parkinson’s dease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 151: 794–796PubMedCrossRefGoogle Scholar
  98. Klawans HL, Goetz CG, Nausieda PA, Weiner WJ (1977) Levodopa-induced dopamine receptor hypersensitivity. Ann Neurol 2: 125–129CrossRefGoogle Scholar
  99. Koller W (1984) Disturbances of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 20: 307–311PubMedGoogle Scholar
  100. Kornhuber J, Weller M (1994) Neuroleptic malignant syndrome. Curr Opin Neurol 7: 353–357PubMedCrossRefGoogle Scholar
  101. Kornhuber J, Weller M, Riederer P (1993) Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic Parkinsonian crisis. J Neural Transm 6: 63–72CrossRefGoogle Scholar
  102. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer W (1995) Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34/7: 713–721CrossRefGoogle Scholar
  103. Korsgaard S, Noring U, Povlsen UJ, Gerlach J (1986) Effects of Citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism. Clin Neuropharmacol 9: 52–57PubMedCrossRefGoogle Scholar
  104. Kostic VS, Filipovic SR, Lesic D, Momcilovic D, Sokic D, Sternic N (1994) Effect of age at onset on frequency of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 57: 1265–1267PubMedCrossRefGoogle Scholar
  105. Kurlan R, Dimitsopulos T (1992) Selegiline and manic behavior in Parkinson’s disease. Arch Neurol 49: 1231PubMedCrossRefGoogle Scholar
  106. Kurland L (1958) Epidemiology: incidence, geographic distribution and genetic considerations. In: Field W (ed) Pathogenesis and treatment of parkinsonism. Charles C Thomas, Springfield, pp 5–43Google Scholar
  107. Laitinen L (1969) Desipramine in the treatment of Parkinson’s disease. Acta Neurol Scand 45: 109–113PubMedCrossRefGoogle Scholar
  108. Lange KW (1999) Cognitive functions in Parkinson’s disease. J Neural Transm 106/1: XXIGoogle Scholar
  109. Leonard BE (1993) The comparative pharmacology of new antidepressants. J Clin Psychiatry 54: 3–15PubMedGoogle Scholar
  110. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253–1260PubMedCrossRefGoogle Scholar
  111. Levin BE, Katzen HL (1995) Early cognitive changes and nondementing behavioral abnormalities in Parkinson’s disease. Adv Neurol 65: 85–95PubMedGoogle Scholar
  112. Levin BE, Llabre MM, Reisman S (1991) A retrospective analysis of the effects of anticholinergic medication on memory performance in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 3: 412–416PubMedGoogle Scholar
  113. Mahieux F, Fénelon G, Flahault A, Manifacier MJ, Michelet D, Boller F (1998) Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64: 178–183PubMedCrossRefGoogle Scholar
  114. Marder K, Flood P, Cote L, Mayeux R (1990) A pilot study of risk factors for dementia in Parkinson’s disease. Mov Disord 5: 156–161PubMedCrossRefGoogle Scholar
  115. Marsh CG, Markham CH (1973) Does levodopa alter depression and psychopathology in parkinsonism patients? J Neurol Neurosurg Psychiatry 36: 925–935PubMedCrossRefGoogle Scholar
  116. Maritila RJ, Kuopio AM, Rinne UK (1994) Survival in Parkinson’s disease: early levodopa treatment enhances life expectancy. Clin Neuropharmacol VIII/1: 120–121Google Scholar
  117. Mayberg HS, Solomon DH (1995) Depression in Parkinson’s disease: a biochemical and organic viewpoint. Adv Neurol 65: 49–60PubMedGoogle Scholar
  118. Mayberg HS, Starkstein SE, Sadzot IB, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN Jr, Robinson RG (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 28: 57–64PubMedCrossRefGoogle Scholar
  119. Mayeux R, Stern Y, Rosen J, Leventhal J (1981) Depression, intellectual impairment, and Parkinson disease. Neurology 31: 645–650PubMedCrossRefGoogle Scholar
  120. Mayeux R, Stern Y, Cote L, Williams JBW (1984) Altered serotonin metabolism in depressed patients with Parkinson’s disease. Neurology 34: 642–646PubMedCrossRefGoogle Scholar
  121. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, Stern Y (1992) A population-based investigation of Parkinson’s disease with and without dementia. Arch Neurol 49: 492–497PubMedCrossRefGoogle Scholar
  122. Mccance-Katz EF, Marek KL, Price LH (1992) Serotonergic dysfunction in depression associated with Parkinson’s disease. Neurology 42: 1813–1814PubMedCrossRefGoogle Scholar
  123. Melamed E, Zoldan J, Friedberg G, Goldberg-Stein H (1993) Is hallucinosis in Parkinson’s disease due to central serotonergic hyperactivity? Mov Disord 8: 406–407Google Scholar
  124. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC (1979) Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 45: 165–175PubMedCrossRefGoogle Scholar
  125. Mendlewicz J, Yahr F, Yahr MD (1976) Psychiatric disorders in Parkinson’s disease treated with 1-dopa: a genetic study. Editiones Roche, Basel, p 103 (Adv Parkinsonism)Google Scholar
  126. Menza MA, Golbe LI, Codi RA, Forman NE (1993) Dopamine-related personality traits in Parkinson’s disease. Neurology 43: 505–508PubMedCrossRefGoogle Scholar
  127. Mindham RHS (1970) Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 33: 188–191PubMedCrossRefGoogle Scholar
  128. Mitscherlich M (i960) The psychic state of patients suffering from parkinsonism. Karger, Basel, pp 317–324 (Adv Psychosom Med)Google Scholar
  129. Mortimer JA, Christensen KJ, Webster DD (1985) Parkinsonian dementia. In: Frederiks JAM (ed) Handbook of clinical neurology 2 (46): neurobehavioral disorders. Elsevier, New York, pp 371–384Google Scholar
  130. Muller SR, Dastoor DP, Klinger A, Boillat J (1979) Amantadine in senile dementia: electroencephalographic and clinical effects. J Am Geriatr Soc 27: 9–16PubMedGoogle Scholar
  131. Mundinger F, Wünsch F (1980) 7-Jahres-Langzeitergebnisse der stereotaktischen Tremorbehandlung beim Parkinson-Syndrom. In: Fischer PA (Hrsg) Parkinson-Syndrom: Kombinations-und Begleittherapien. Fischer, Stuttgart New York, S 199–209Google Scholar
  132. Naber D, Leppig M, Grohmann R, Hippius H (1989) Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — a retrospective study of 387 patients. Psychopharmacology 99: 73–76CrossRefGoogle Scholar
  133. Nahmias C, Garnett ES, Firnau G, Lang A (1985) Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 69: 223–230PubMedCrossRefGoogle Scholar
  134. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL (1982) Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 5: 183–194PubMedCrossRefGoogle Scholar
  135. Ng LKY, Chase TN, Colburn RW, Kopin IJ (1972) Release of 3H-dopamine by L-5-hydroxytryptophan. Brain Res 45: 499–505PubMedCrossRefGoogle Scholar
  136. Nies A, Robinson DS, Friedman MJ, Green R, Cooper TB, Ravaris CL, Ives JO (1977) Relationship between age and tricyclic antidepressant plasma levels. Am J Psychiatry 134: 790–793PubMedGoogle Scholar
  137. Olichneyj M, Douglas G, Corey-Bloom J, Thal LJ (1995) The spectrum of diseases with diffuse lewy bodies. Adv Neurol 65: 159–170Google Scholar
  138. Paulus W, Jellinger K (1991) The neurpathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50: 743–755PubMedCrossRefGoogle Scholar
  139. Peuch A (1993) Contributions of pharmacology in the treatment of resistance to antidepressive agents. Encephale 19: 407–412Google Scholar
  140. Pillhatsch K (1995) Korrelation des organischen Psychosyndroms im Alter mit apparativen Befunden — Aussagekraft von EKG und CCT bei psychiatrischen Erkrankungen im Alter. 2 Gerontol 18: 330–336Google Scholar
  141. Poewe W, Karamat E, Kemmler G W, Gerstenbrand F (1990) The premorbid personality of patients with Parkinson’s disease: a comparative study with healthy controls and patients with essential tremor. Adv Neurol 53: 339–342PubMedGoogle Scholar
  142. Post F (1962) The significance of affective symptoms in old age [Maudsley Monograph 10]. Oxford University Press, LondonGoogle Scholar
  143. Prick JJG (1966) Genuine parkinsonism. A psychosomatic, anthropological-psychiatric approach. Abs Work Congress of Psychiatry Madrid, Sandorama Special Number IVGoogle Scholar
  144. Rajput A, Offord K, Beard C, Kurland L (1984) Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 16: 278–283PubMedCrossRefGoogle Scholar
  145. Rajput AH, Uitti RJ, Ho M, Offord K, Rajput A, Basran P (1994) Current survival profile in parkinsonism. Clin Neuropharmacol VIII/1: 121–122Google Scholar
  146. Riederer P, Lange KW, Kornhuber J, Danielczyk W (1992) Glutamatergic-dopaminergic balance in the brain. Arzneimittelforschung/Drug Res 42(I), 2a: 265–268Google Scholar
  147. Robins AH (1986) Depression in patients with parkinsonism. Br J Psychiatry 128: 141–145CrossRefGoogle Scholar
  148. Ruggieri S, Fabbrini G, Bramante L, DePandis, Stocchi, Barbanti P, Vacca L, Manfredi M (1996) An open study with reversible MAO-A inhibitors in complicated Parkinson’s disease. Adv Neurol 69: 595–598PubMedGoogle Scholar
  149. Russ M, Fischer PA (1994) Sind die kognitiven Störungen des Parkinson-Kranken „dopaminerg“? In: Fischer PA (Hrsg) Parkinson-Krankheit, Bedeutung nichtdopaminerger FunktionsstÖrungen. Editiones Roche, Basel, S 133–153Google Scholar
  150. Rückert W (1984) BevÖlkerungsentwicklung und Altenhilfe von der Kaiserzeit bis zum Jahre 2000. Kuratorium Deutsche Altenhilfe, KÖln, S 98Google Scholar
  151. Sadah M, Braham J, Madan M (1982) Effects of anticholinergic drugs on memory in Parkinson’s disease. Arch Neurol 39: 666–667CrossRefGoogle Scholar
  152. Santamaria J, Tolosa E, Valles A (1986) Parkinson’s disease with depression: a possible subgroup of idipathic parkinsonism. Neurology 36: 1130–1133PubMedCrossRefGoogle Scholar
  153. Schneider E (1999) Therapy of depression and pharmacotoxic psychosis. J Neural Transm 106/1: XXXGoogle Scholar
  154. Schneider E, Fischer PA, Jacobi P, Grotz A (1984) Exogene Psychosen beim Parkinson-Syndrom. Häufigkeit und Entstehungsbedingungen. Fortschr Neurol Psychiat 52: 207–214CrossRefGoogle Scholar
  155. Schoenberg B, Anderson D, Haerer A (1985) Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 35: 841–845PubMedCrossRefGoogle Scholar
  156. Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235: 60–64CrossRefGoogle Scholar
  157. Schwab RS, Fabing HD, Prichard JS (1950) Psychiatric symptoms and syndromes in Parkinson’s disease. Am J Psychiatry 107: 901–907Google Scholar
  158. Schwab RS, England AC Jr, Poskaner DC (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc 208: 1168–1170CrossRefGoogle Scholar
  159. Siemers ER, Schekhar A, Quaid K, Dickson H (1993) Anxiety and motor performance in Parkinson’s disease. Mov Disord 8: 501–506PubMedCrossRefGoogle Scholar
  160. Spicer KB, Roberts RJ, Le Witt PA (1988) Neuropsychological performance in lateralized parkinsonism. Arch Neurol 45: 429–432PubMedCrossRefGoogle Scholar
  161. Starkstein SE, Berthier ML, Bolduc PL, Preziosi TJ, Robinson RG (1989a) Depression in patients with early versus later onset of Parkinson’s disease. Neurology 39: 1141–1145CrossRefGoogle Scholar
  162. Starkstein SE, Robinson RG, Honig MA, Parikh RM, Joselyn J, Price TR (1989b) Mood changes after right hemisphere lesions. Br J Psychiatry 155: 79–85PubMedCrossRefGoogle Scholar
  163. Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG (1990a) Cognitive impairments and depression in Parkinson’s disease: a follow-up study. J Neurol Neurosurg Psychiatry 53: 597–602PubMedCrossRefGoogle Scholar
  164. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990b) Depression in Parkinson’s disease. J Nerv Ment Dis 178: 21–31CrossRefGoogle Scholar
  165. Starkstein SE, Mayberg HS, Preziosi TJ, Anrezejewski P, Leiguarda R, Robinson RG (1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s diseases. J Neuropsychiat Clin Neurosci 4: 134–139Google Scholar
  166. Stenager EN, Wermuth L, Stenager E, Boldsen J (1994) Suicide in patients with Parkinson’s disease. An epidemiological study. Acta Psychiatr Scand 90: 70–72PubMedCrossRefGoogle Scholar
  167. Strang RR (1965) Imipramine in the treatment of parkinsonism: a double-blind placebo study. Br J Med 2: 33–34CrossRefGoogle Scholar
  168. Strauss WH, Klieser E, Luethke H, Burtscheidt W (1988) Dyscognitive syndrome in neuroleptic therapy. Pharmacopsychiatry 21: 298–299PubMedCrossRefGoogle Scholar
  169. Streifler M, Hait Z (1973) Amantadinderivate bei Parkinsonismus im Blindversuch. Ther Woche 40: 3549–3652Google Scholar
  170. Suchowersky O, Devries J (1990) Possible interaction between deprenyl and prozac [Letter]. Can J Neurol Sci 17: 352–353PubMedGoogle Scholar
  171. Swanson PD (1994) Drug treatment of Parkinson’s disease: is „polytherapy“ best? J Neurol Neurosurg Psychiatry 57: 401–403PubMedCrossRefGoogle Scholar
  172. Tate JL (1989) Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 146: 399–400PubMedGoogle Scholar
  173. Tatemichi TK, Sacktor N, Mayeux R (1994) Dementia associated with cerebrovascular disease, other degenerative disease, and metabolic disorders. In: Terry RD, Katzmann R, Slick KL (eds) Alzheimer disease. Raven Press, New York, pp 123–166Google Scholar
  174. Tiffany T, Cummings JL (1998) Depression in Parkinson’s disease. Pharmacological characteristics and treatment. Drugs & Aging 12: 55–74CrossRefGoogle Scholar
  175. Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B (1989) Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12: 375–383PubMedCrossRefGoogle Scholar
  176. Uitti R J, Rajput AH, Ahlskog JE, Offord KP, Ho MM, Prasad M, Rajput A, Basran P (1993) Amantadine treatment is an independent predictor of improved survival in parkinsonism. Can J Neurol Sci 20[Suppl 4]: 235Google Scholar
  177. van Tol HHM, Bunzow JR, Guan H-C et al. (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614PubMedCrossRefGoogle Scholar
  178. Venkateswarlu T, Staley CJ, Neal CD (1990) Zuclopenthixol dihydrochloride in the management of behavioural disorders in elderly demented patients: a dose-ranging study. Int J Geriatr Psychiatry 5: 265–270CrossRefGoogle Scholar
  179. Vogel HP (1982) Symptoms of depression in Parkinson’s disease. Pharmacopsychiatry 15: 192–196CrossRefGoogle Scholar
  180. Warborton JW (1967) Depressive symptoms in Parkinson patients referred for thalamotomy. J Neurol Neurosurg Psychiatry 30: 368–370CrossRefGoogle Scholar
  181. Wolters ECH, Hurwitz TA, Peppard RF, Calne DB (1989) Clozapine: an antipsychotic agent for Parkinson’s disease? Clin Neuropharmacol 12: 83–90PubMedCrossRefGoogle Scholar
  182. Wong DT, Bymaster FP, Reid LR, et al. (1983) Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 32: 1287PubMedCrossRefGoogle Scholar
  183. Yahr MD, Duvoisin RC, Scheer MJ, Barrett RE, Hoehn MM (1969) Treatment of parkinsonism with levodopa. Arch Neurol (Chic) 21: 343–354CrossRefGoogle Scholar
  184. Yaryura-Tobias JA, Diamond B, Merlis S (1970) Psychiatric manifestations of levodopa. Dis Nerv Syst 31: 60–63PubMedGoogle Scholar
  185. Young RC, Alexopoulos GS, Shamoian CA (1985) Dissociation of motor response from mood and cognition in a parkinsonian patient treated with ECT. Biol Psychiatry 20: 566–569PubMedCrossRefGoogle Scholar
  186. Yudofsky SC (1979) Parkinson’s disease, depression, and electroconvulsive therapy: a clinical and neurobiologie synthesis. Compr Psychiatry 20: 579–581PubMedCrossRefGoogle Scholar
  187. Zetusky W, Jankovic J, Pirozzolo F (1985) The heterogeneity of Parkinson’s disease: clinical and prognostic implications. Neurology 35: 1222–1224CrossRefGoogle Scholar
  188. Zoldan J, Friedberg G, Weizman A, Melamed E (1996) Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-Dopa therapy in advanced Parkinson’s disease. Adv Neurol 69: 541–544PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • W. Danielczyk

There are no affiliations available

Personalised recommendations